TransCode Therapeutics (RNAZ)
5.40
-0.11 (2.00%)
Upcoming Events
Latest Headlines
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
June 8, 2026 8:04 AM - PR NewsWire
Form 8-K Transcode Therapeutics, For: Jun 03
June 3, 2026 8:09 AM - SEC Filing
TransCode completes phase 1a cancer trial with no dose-limiting toxicities
June 3, 2026 8:04 AM - StreetInsider
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
June 3, 2026 8:04 AM - PR NewsWire
Form ARS Transcode Therapeutics, For: Dec 31
June 2, 2026 4:18 PM - SEC Filing
Form DEF 14A Transcode Therapeutics, For: Jul 02
June 2, 2026 4:06 PM - SEC Filing
Form 8-K Transcode Therapeutics, For: May 29
June 1, 2026 9:00 AM - SEC Filing
TransCode starts phase 2a trial for colorectal cancer drug
May 27, 2026 8:04 AM - StreetInsider
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
May 27, 2026 8:04 AM - PR NewsWire
Form DEFA14A Transcode Therapeutics,
May 26, 2026 6:46 AM - SEC Filing
Form 8-K/A Transcode Therapeutics, For: May 19
May 26, 2026 6:44 AM - SEC Filing
Form 8-K Transcode Therapeutics, For: May 19
May 22, 2026 4:16 PM - SEC Filing
Form EFFECT Transcode Therapeutics,
May 20, 2026 6:04 AM - SEC Filing
Form EFFECT Transcode Therapeutics,
May 20, 2026 6:04 AM - SEC Filing
Form 10-Q Transcode Therapeutics, For: Mar 31
May 15, 2026 4:16 PM - SEC Filing
Form PRE 14A Transcode Therapeutics, For: May 08
May 8, 2026 5:21 PM - SEC Filing
Form S-1 Transcode Therapeutics,
May 1, 2026 9:50 AM - SEC Filing
Form S-3 Transcode Therapeutics,
April 30, 2026 5:26 PM - SEC Filing
Form 10-K/A Transcode Therapeutics, For: Dec 31
April 30, 2026 4:20 PM - SEC Filing
TransCode Therapeutics names Dr. Anna Moore board chair, signs MSU deal
April 27, 2026 8:02 AM - StreetInsider
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
April 27, 2026 8:02 AM - PR NewsWire
Form SCHEDULE 13G Transcode Therapeutics, Filed by: YA II PN, Ltd.
April 20, 2026 4:57 PM - SEC Filing
Form 10-K Transcode Therapeutics, For: Dec 31
April 15, 2026 4:19 PM - SEC Filing
Form DEFA14A Transcode Therapeutics,
April 7, 2026 12:54 PM - SEC Filing
Form 8-K Transcode Therapeutics, For: Apr 06
April 7, 2026 12:53 PM - SEC Filing
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
April 7, 2026 12:43 PM - PR NewsWire
TransCode Therapeutics secures up to $20 million financing agreement
April 7, 2026 8:32 AM - StreetInsider
Form NT 10-K Transcode Therapeutics, For: Dec 31
March 31, 2026 4:15 PM - SEC Filing
Full Article List
